Skip to main content

Table 3 Multivariable adjusted risks of CHD and hard CHD based on different glucose intolerance categories. (n = 408)

From: Long term prognostic implication of newly detected abnormal glucose tolerance among patients with stable cardiovascular disease: a population-based cohort study

  CHD HR (95%CI) Hard CHD HR (95%CI)
E/N Model 1 Model 2 E/N Model 1 Model 2
FPG-WHO (mmol/L)
  < 6.1 156/327 1.00 1.00 41/327 1.00 1.00
 6.1–6.9 19/44 0.89 (0.55–1.43) 0.83 (0.51–1.35) 7/44 1.27 (0.57–2.84) 1.01 (0.44–2.32)
  ≥ 7 27/37 1.89 (1.25–2.87) 1.97 (1.28–3.03) 10/37 2.31 (1.15–4.62) 2.56 (1.21–5.39)
FPG-ADA (mmol/L)
  < 5.6 120/253 1.00 1.00 30/253 1.00 1.00
 5.6–6.9 55/118 1.04 (0.75–1.43) 1.02 (0.73–1.41) 18/118 1.39 (0.77–2.49) 1.30 (0.71–2.40)
  ≥ 7 27/37 1.94 (1.27–2.97) 2.03 (1.30–3.16) 10/37 2.50 (1.22–5.12) 2.84 (1.31–6.19)
2 h-PCPG (mmol/L)
  < 7.8 112/240 1.00 1.00 31/240 1.00 1.00
 7.8–11.0 51/105 1.02 (0.73–1.42) 1.00 (0.70–1.40) 13/105 0.97 (0.51–1.85) 0.93 (0.47–1.83)
  ≥ 11 39/63 1.46 (1.01–2.11) 1.46 (1.00–2.15) 14/63 1.91 (1.01–3.60) 1.95 (0.99–3.85)
  1. Model 1: age and sex
  2. Model 2: model 1+ body mass index, current smoking, family history of premature CVD, hypertension, hypercholesterolemia, low HDL-C, heart rate, use of aspirin, use of beta blockers and low physical activity.
  3. E event in the target group, N total sample size in the target group, CVD cardiovascular disease, CHD coronary heart disease, HR hazard ratio, CI confidence interval, FPG fasting plasma glucose, 2h-PCPG 2h post challenge plasma glucose, WHO World Health Organization, ADA American Diabetes Association